2-(Ethylamino)-1,2-diphenylethanone
2-(Ethylamino)-1,2-diphenylethanone (also known as α-ethylamino-deoxybenzoin, [α-(Ethylamino)benzyl]-(phenyl)-ketone and βk-Ephenidine) is a chemical compound which was first invented in 1955,[1] researched by ICI in 1969 as an antidepressant,[2] and subsequently claimed by AstraZeneca as an inhibitor of the enzyme 11β-Hydroxysteroid dehydrogenase type 1.[3] No other pharmacological data has been disclosed, though its chemical structure closely resembles that of certain designer drug compounds such as ephenidine and N-ethylhexedrone.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C16H17NO |
Molar mass | 239.318 g·mol−1 |
3D model (JSmol) | |
| |
|
References
- Hinderling R, Prijs B, Erlenmeyer H. Über α‐Alkylamino‐ketone. Helvetica Chimica Acta 1955; 38(6):1415-1420. doi:10.1002/hlca.19550380613
- Gilman DJ. Desyl amines and compositions thereof. Patent GB 1143263, 1969.
- Barton P, et al. Ketones. Patent US 2005/0272036
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.